文献速递瓣膜外科

退变生物瓣的瓣中瓣TAVI与再次外科主动脉瓣置换的系统评价与荟萃分析

Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis.
PubMed 文献 · Eur J Cardiothorac Surg · 2018-01-01

该系统评价与荟萃分析纳入5项观察性研究(n=342),比较瓣中瓣TAVI与再次外科主动脉瓣置换治疗退变生物瓣。ViV TAVI组患者更年长且基线风险更高,累积生存分析倾向于外科手术(HR 1.91,95%CI 1.03-3.57;P=0.039),但ViV TAVI组永久起搏器植入率更低且ICU和住院时间更短。

要点

  • ViV TAVI与再次外科主动脉瓣置换在手术死亡率、30天死亡率和心血管死亡率上无统计学差异。
  • 累积生存分析倾向于再次外科主动脉瓣置换,差异有边缘统计学意义(HR 1.91,P=0.039)。
  • ViV TAVI永久起搏器植入率更低,ICU和住院时间更短,但再次外科主动脉瓣置换血流动力学结果更优。

核心结论

  • ViV TAVI是再次外科主动脉瓣置换安全可行的替代方案,可能为无法手术或高危的退变生物瓣患者提供有效、创伤更小的治疗。
  • 再次外科主动脉瓣置换仍应是标准治疗,尤其在低危人群中,因其提供更优的血流动力学结果且死亡率低。

研究设计与样本

  • 系统评价与荟萃分析,检索多个数据库比较ViV TAVI与再次外科主动脉瓣置换的报道。
  • 纳入5项观察性研究,共342例患者;ViV TAVI组患者更年长且基线风险更高。
  • 主要结局为基于最长可用生存数据的全因死亡率。

主要发现

  • 手术死亡率无统计学差异(RR 0.74,95%CI 0.18-2.97;P=0.67)。
  • 30天死亡率无统计学差异(RR 1.29,95%CI 0.44-3.78;P=0.64)。
  • 平均随访18个月的心血管死亡率无统计学差异(RR 0.91,95%CI 0.30-2.70;P=0.86)。
  • 累积生存分析倾向于外科手术,有边缘统计学意义(ViV TAVI对比再次外科主动脉瓣置换:HR 1.91,95%CI 1.03-3.57;P=0.039)。
  • ViV TAVI永久起搏器植入率显著更低(RR 0.37,95%CI 0.20-0.68;P=0.002),ICU停留(P<0.001)和住院时间(P=0.020)更短。

临床怎么用

  • 对于无法手术或高危的退变生物瓣患者,ViV TAVI可作为再次外科主动脉瓣置换的安全可行替代方案。
  • 在低危人群中,再次外科主动脉瓣置换仍应作为标准治疗,因其血流动力学结果更优且死亡率低。

局限性

  • 仅纳入5项观察性研究,样本量小(n=342),存在选择偏倚可能。
  • ViV TAVI组患者更年长且基线风险更高,可能影响结局比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of this report was to directly compare, by means of a systematic review and meta-analysis, redo surgical aortic valve replacement (re-sAVR) with valve-in-valve transcatheter aortic valve implantation (ViV TAVI) for patients with failed degenerated aortic bioprostheses. Multiple databases were screened for all available reports comparing ViV TAVI with re-sAVR in patients with failing degenerated aortic bioprostheses. The primary outcome was all-cause mortality determined from the longest available survival data. Five observational studies (n = 342) were included in the meta-analysis; patients in the ViV TAVI group were older and had a higher baseline risk compared to those in the re-sAVR group. Although there was no statistical difference in procedural mortality [risk ratio (RR) 0.74, 95% confidence interval (CI) 0.18-2.97; P = 0.67], 30-day mortality (RR 1.29, 95% CI 0.44-3.78; P = 0.64) and cardiovascular mortality (RR 0.91, 95% CI 0.30-2.70; P = 0.86) at a mean follow-up period of 18 months, cumulative survival analysis favoured surgery with borderline statistical significance (ViV TAVI versus re-sAVR: hazard ratio 1.91, 95% CI 1.03-3.57; P = 0.039). ViV TAVI was associated with a significantly lower rate of permanent pacemaker implantations (RR 0.37, 95% CI 0.20-0.68; P = 0.002) and shorter intensive care unit (P < 0.001) and hospital stays (P = 0.020). In contrast, re-sAVR offered superior echocardiographic outcomes: lower incidence of patient-prosthesis mismatch (P = 0.008), fewer paravalvular leaks (P = 0.023) and lower mean postoperative aortic valve gradients in the prespecified analysis (P = 0.017). The ViV TAVI approach is a safe and feasible alternative to re-sAVR that may offer an effective, less invasive treatment for patients with failed surgical aortic valve bioprostheses who are inoperable or at high risk. Re-sAVR should remain the standard of care, particularly in the low-risk population, because it offers superior haemodynamic outcomes with low mortality rates.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Gozdek M, Raffa GM, Suwalski P, et al. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. Eur J Cardiothorac Surg. 2018. PMID: 29029105. doi:10.1093/ejcts/ezx347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。